BTL-TML001

Drug Profile

BTL-TML001

Alternative Names: BTL TML001; BTL-TML-HSV

Latest Information Update: 25 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beech Tree Labs
  • Class Antivirals; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes labialis
  • Phase I/II Herpes simplex virus infections
  • No development reported Influenza virus infections

Most Recent Events

  • 25 Sep 2015 Combined efficacy data from two phase II trials in Herpes simplex virus infections released by Beech Tree Labs
  • 16 Sep 2015 No recent reports of development identified - Phase-I/II for Influenza virus infections in USA (unspecified route)
  • 01 Feb 2015 Beech Tree Labs completes a phase II trial in Herpes labialis (Recurrent) in USA (sublingual) (NCT01902303)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top